

526,972

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
13 January 2005 (13.01.2005)

PCT

(10) International Publication Number
WO 2005/002609 A1

(51) International Patent Classification⁷: **A61K 35/78,**
A61P 15/12

(21) International Application Number:
PCT/CH2004/000405

(22) International Filing Date: 28 June 2004 (28.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1162/03 1 July 2003 (01.07.2003) CH

(71) Applicant (for all designated States except US): **MAX
ZELLER SÖHNE AG** [CH/CH]; Seeblickstrasse 4,
CH-8590 Romanshorn (CH).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **BRATTSTRÖM,**
Axel [DE/DE]; Ackerweg 6, 78476 Allensbach (DE).

(74) Agent: **RITSCHER, Thomas**; Ritscher & Partner AG,
Zollikerstrasse 19 / PO Box 372, CH-8029 Zürich (CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PLANT EXTRACTION METHOD AND EXTRACT



(57) Abstract: A plant extract from a medical
plant, preferably from *Cimicifuga racemosa*, is
produced by treating a solid plant material with an
extraction agent, preferably an aqueous alcanol,
to obtain an extraction liquid containing the extract
dissolved in said extraction agent; separating said
extraction liquid from said solid plant material;
and concentrating said extraction liquid by at
least partially removing said extraction agent to
produce a concentrated extract. According to the
invention, concentrating the extraction liquid is
effected in the presence of an effective amount of
a pharmacologically acceptable and physiologically
inert solution mediator. This yields a novel extract
and avoids loss of constituents of the extract liquid
upon concentration thereof. The extract obtained
is can be used as a medication capable of binding
estrogen receptors as well as progesterone receptors
and is effective for treating climacteric and post

menopausal distress.

BEST AVAILABLE COPY

WO 2005/002609 A1

PLANT EXTRACTION METHOD AND EXTRACT

The present invention generally concerns the art of producing extracts from medicinal plants and, specifically, production of extracts from medicinal plants which contain a substantial portion, at least, of triterpene glycosides and/or triterpene saponines as active ingredients.

Important examples of this type of medicinal plants are the *Cimicifuga species*, e.g. *Cimicifuga racemosa* (also termed *Actaea racemosa* L.; black cohosh; cohosh bugbane; snakeroot; bugbane) since extracts from various parts of this plant species are known to be effective as analgesics for treatment of pain in muscles and joints, as well as to treat neuralgic diseases rheumatic arthritis, menstrual discomfort, and post-natal pains.

For example, such extracts have been disclosed in WO 99/47149 as an organo-selective estrogen-type medicament for selective treatment and/or prophylaxis of cardiovascular diseases and climacteric discomfort. However, no uterotrophic effects have been observed.

Further, US 6,267,994 discloses use of an extract from *Cimicifuga racemosa*, notably for anti-tumour therapy in compositions that do not exhibit the toxicity of high doses of anti-estrogenic compounds.

Finally, WO 01/05415 discloses a pharmaceutical composition containing components of *Cimicifuga racemosa* extract or derivatives thereof that exhibit an estrogen-type effect.

Conventional methods of producing such extracts are based upon treatment of plant material with an aqueous alcanolic extracting agent so as to obtain a raw or primary extract which after an optional treatment for removal of fines, e.g. by sedimentation or filtration, which contains the extracting agent and the plant constituents that are soluble in the extracting agent.

Typically, the primary extract is then concentrated by partial evaporation of the extracting agent so as to remove its more volatile components, generally the alcanolic constituents plus some water, and to form what is called a concentrated extract, typically containing 5 – 50 % by volume, of residual solvent, i.e. water. Upon further removal of solvent, a solid, pasty, or liquid material is obtained that is substantially free of the solvent used for extraction of the plant material. This product (also termed “ex-

tract") can then be used as such or processed to produce specific application form, e.g. pills, lotions, solutions, powders etc., optionally adding whatever adjuvants, additives, coating components and the like are needed for the final medicinal product.

Research by applicant leading to the present invention has shown that conventional production methods of extracting medicinal plants that contain a substantial portion, at least, of triterpene glycosides and/or triterpene saponines tend to suffer from a loss of active ingredients and/or yield an inhomogeneous product, and that this is due to unintended precipitation upon solvent removal. *Cimicifuga species* are an important example of such medicinal plants but not the only one.

Active ingredients of *Cimicifuga racemosa* include triterpene glycoside of the cycloartan-type of which at least 20 species are known. A main ingredient is acteine, 23-epi-26-deoxyactein, 27-deoxyactin and cimracemoside A. Actein is a xyloside of acetyl acteol with a 16,23:23,26:24,25-triepoxy side chain. 27-Deoxyactine is used as a standard for quantitative determination of the compounds just mentioned. A further known group of active ingredients are aromatic acids such as ferulic acid, hesperatinic acid and acyl caffeinic acid. Further, the following esters of hydroxy cinnamic acid have been isolated from aqueous ethanolic extracts of *Cimicifuga racemosa*: fucinolic acid and the cimicifugaic acids A, B, E und F. Flavonoides, biochanine A, formononetine and camphorol have also been reported. Other ingredients are tannins, resins and fatty acids (oleic acid, linolic acid, linolenic acid and palmitinic acid).

With such a large number of constituents it is easily understandable that extraction conditions will have a substantial impact upon the composition of the resulting extracts and that any unintended change of the proportional makeup is undesirable.

Accordingly, it is a first object of the present invention to provide for a new method of extracting such medicinal plants that contain a substantial portion, at least, of triterpene glycosides and/or triterpene saponines, which method is capable of preventing such loss of active ingredients upon solvent removal so as to yield novel extracts of improved composition.

Another object of the invention is an extract of *Cimicifuga species* such as *Cimicifuga racemosa* having a composition that differs from prior art extracts.

A further object of the invention is to provide for medicaments comprising such extracts, as well as for medical treatment of diseases in animal patients including humans using such extracts.

It has been found, according to the invention, that novel extracts including, but not restricted to, those obtainable from various parts of the plant species *Cimicifuga* differing in composition from prior art extracts can be obtained if such unintended precipitation is prevented, and that such prevention can be effected if removal of the extracting solvent is effected in the presence of a solution mediator.

Now, according to a first general embodiment the invention provides for a method of producing a vegetal plant extract by the steps of:

- (A) treating a material (e.g. leaves, roots, stems, branches, seeds) of a medical plant, preferably a *Cimicifuga species*, with an extraction agent to obtain a primary extract;
 - (B) separating said primary extract from said solid material; and
 - (C) concentrating said primary extract for removing a portion, at least, of said extraction agent for obtaining an essentially homogeneous concentrate;
- wherein said step (C) of concentrating said primary extract is effected in the presence of an effective amount of a pharmacologically acceptable and physiologically inert solution mediator so as to substantially avoid loss of constituents of said primary extract.

According to a preferred embodiment of the inventive method, the product obtained in step (C) is subjected to a further treatment for substantially removing all of the extraction agent, preferably by spray drying, to obtain an essentially dry product.

Medical plants other than *Cimicifuga species* for use in preparing extracts according to the inventive method include *Hedera*, *Liquorice*, *Symphytum*, *Centella asiatica*, *Ginseng* and *Solidago*. Generally, all medical plant extracts can benefit from the inventive teaching of adding a solution mediator prior to concentration provided that the solution mediator does not form a precipitate with constituents of the extract, e.g. tannic acids in the case of the preferred solution mediator for *Cimicifuga sp.*

Generally, the term "extract" as used herein without further specification is intended to generally refer to any form of the product of extraction minus the extracting agent and regardless of the physical form (i.e. viscous, pasty or solid).

Suitable solution mediators for use in the invention are macromolecular substances or polymers known to be admissible for use in medicaments and to be physiologically inert as well as soluble in the extraction agent and in water. The term "soluble" as used herein does not necessarily indicate complete solubility but a partial solubility in the extraction agent as well, as is generally apparent from the fact that the solu-

tion mediator is capable of being dissolved in the extraction agent at temperatures between 0°C and 100 °C at ambient pressure so as to form a „normal“ (clear) or „colloidal“ (turbid) solution, also termed a colloidal or molecular dispersion. Preferably, the solution mediator should be capable of forming an aqueous solution which, at room
5 temperature, contains at least about 30% by weight of the solution mediator.

The molecular mass of such a polymer solution mediator generally is in the range of from about 1'000 to about 1'300'000 Dalton. A minimum molecular mass of suitable solution mediators of about 5'000 Dalton is preferred for many purposes of the invention.

10 According to the invention, a group of preferred solution mediators for alcanolic or alcanol/water as extraction agents is the family of compounds known as poly(vinylpyrrolidone) also known as povidone or PVP. Such polymers admitted under current food and drug regulations for pharmaceutical or food use are available commercially from various sources.

15 As has been shown in many studies, PVP when ingested by humans has no negative effects and is not digested or metabolized. When taken orally, the predominant portion thereof is excreted within 11 hours and no PVP enrichment has been observed.

While PVP is preferred for use in polar extraction agents including those containing water, other water soluble polymers of synthetic, semi-synthetic or natural provenience can be used as solution mediators according to the invention, e.g. polyvinyl alcohol as well as cellulose derivatives that are soluble or, at least, capable of swelling in
20 water and the like polymers, as long as they are physiologically inert, i.e. do not significantly affect the human organism when ingested.

Addition of a solution mediator, such as PVP, not only prevents agglomeration
25 and subsequent precipitation of less soluble components of the primary extract upon concentration in the manner of a protective colloid but additionally to retain the entire content of the plant extract upon complete removal of the extraction agent without loss of extracted plant components.

An effective amount of solution mediator according to the invention generally is
30 in the range of from about 5 % by weight to about 50 % by weight, based upon the weight of the final extract. A range of from about 15 % by weight to about 35 % by weight, is preferred for many purposes.

Preferably, the extraction agent is a polar substance, such as a normally liquid alcohol, e.g. methanol, ethanol, propanol, butanol as well as mixtures of such C₁₋₄ alcohols with each other and/or with water. Mixtures of from about 40 to about 80 %, by weight, of such alcohol, preferably ethanol, with about 60 to about 20 %, by weight, of water are preferred for many purposes. Whenever the qualifier "about" is used herein, it is intended to include a variation of $\pm 30\%$, preferably $\pm 10\%$, from the value associated with this qualifier.

Other solution mediators have been found to be effective, however, generally less so in obtaining extracts from *Cimicifuga* sp. Examples of such other solution mediators include: hydroxyethyl cellulose (optionally in mixture with lecithin), maltodextrin, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, fructose, tartaric acid (optionally in the form of a salt, e.g. sodium salt).

Preferably, the solution mediator is added to the primary extract rather than to the extraction agent. The extraction procedure may be carried out in conventional apparatus. In any case, the solution mediator is added prior to any significant removal of extraction agent. Such removal or concentration can be effected in a known manner, e.g. by distillation at an elevated temperature and/or reduced pressure taking care to avoid conditions that could affect the components of the extract. Concentration may be effected at constant or varying conditions of temperature and/or pressure.

A preferred embodiment of the inventive process is carried out by extraction of the dry plant material with an ethanol-water mixture containing about 50 - 60 %, by volume, of ethanol and about 50 - 40 %, by volume, of water. Upon concentration, the alcoholic constituents plus any water of an azeotropic mixture is removed until a solids concentration of about 25 - 50 %, by weight, is reached. The concentrated extract obtained may then be processed in any conventional manner, e.g. by spray-drying to form a dry product. During such a final concentration step, e.g. upon spray-drying the solution mediator, such as PVP, additionally acts as a spray-drying adjuvant. Generally, the solution mediators has the effect that a homogeneous consistence of the extract is maintained in all stages of the concentration process.

Extracts of *Cimicifuga racemosa* obtained as disclosed herein can be used according to the invention for production of a medicament suitable for treating climacteric and post menopausal distress. Such preparation can be effected in conventional manner

except that the extract used has been obtained in the presence of the solution mediator according to the invention.

Such a medicament is suitable as a substitute or complement of a hormone replacement therapy, and is capable of alleviating climacteric and menopausal symptoms, therefore it can generally be applied for treating climacteric and post menopausal distress in a female human patient.

A medicament according to the invention normally contains the novel extract as an at least dominant portion in combination with other conventional and well-known components of medicaments which, in turn, may but need not be pharmaceutically active. On the other hand, a medicament according to the invention may substantially consist of the novel extract, e.g. in a liquid or solid diluent.

It has been found according to the invention that the physiological effectiveness of the novel extract can be determined by a relatively simple measuring method, namely by measuring the pulse frequency of an epithelia sample taken from the oviduct as known in the art of determining the effectiveness of hormone treatment (e.g. Mahmood, T. et al. "The effect of ovarian steroids on epithelial ciliary beat frequency in human fallopian tube" (1998), Human Reproduction, 13(11); 2991 – 2994)

The extract according to the invention can be used to prepare medicaments with an effect similar to that of progesterone effective for treatment of climacteric or postmenopausal discomfort in female human patients. To this end, the extract according to the invention can be processed, in a manner known per se from standard pharmacological practice to obtain conventional application forms and applied for medical treatment in the dosages known for use of conventional extracts of *Cimicifuga racemosa*, e.g. in the broad range of from about 0.1 to about 100 mg/kg of body weight. Clinical tests in treating female human patients with menopausal syndrome (cf. example 5 below) gave favorable results when used at a dosage of 6.5 mg and 13 mg/day.

The invention will now be explained in more detail with reference to the enclosed drawing in which:

5 Figure 1 is a diagram of an LC-analysis of a conventionally prepared extract of *Cimicifuga racemosa*;

Figure 2 is a diagram of an LC-analysis obtained under the same general conditions as in Fig. 1, however with an extract of *Cimicifuga racemosa* obtained according to the invention by concentration in the presence of a solution mediator; and

10 Figure 3 is a diagram showing results of clinical testing.

In the following examples given by way of illustration not limitation, indications in percent or parts are based upon the weight unless specifically mentioned otherwise.

15 Example 1

Preparation of the extract

Dry root material of *Cimicifuga racemosa* (rhizome) were processed by milling to obtain a powder and charges of material from different harvests were combined for homogeneity.

20 Extraction was performed on the basis of a ratio of 2'500 parts extraction agent per 500 parts of *Cimicifuga racemosa*. The extraction agent, in turn, was prepared by mixing 1'330 parts of ethanol (96%, by volume) and 1' 170 parts of de-ionized water.

Water and ethanol of ambient temperature were mixed in a container provided with a mechanical stirrer and a withdrawal port at the bottom of the container. Then, the
25 *Cimicifuga racemosa* powder was added with continued stirring, and stirring was continued for 300 minutes. Then, the stirrer was stopped and the solids allowed to settle which normally takes about 180 minutes and, in any case, is continued until a clear supernatant has been formed above the sediment.

The clear supernatant is removed by means of a pump and collected in a separate
30 container. The sediment is fed into a filter press to recover additional extraction liquid which is combined with the supernatant and the resulting mixture is fed through a filter into a mixing container provided with a stirrer and a weighing device. After starting of the poly(vinylpyrrolidone) (termed PVP herein, a commercial product sold under the

trade name Plasdone® KW 29-32) is added in an amount of 33 parts per 100 parts of extraction liquid and stirring is continued until the PVP has dissolved and a clear brown liquid is obtained as a first product.

This product is fed into a standard-type two-stage concentrator plant type KV 102 EX produced and sold by Unipektin AG, Eschenz, Switzerland, in which the extraction liquid including the PVP is concentrated by evaporation of the extraction agent to yield a dark brown concentrate having a concentration of at least about 9% solids which is then further concentrated to form a spissum extract having a solids content between about 18 and 26 %. Then, the concentrate is fed into a conventional spray-dryer to produce a dry extract in the form of a powder with a humidity content of not more than about 5% by weight.

Both the concentrated liquid spissum extract as well as the dry pulverulent extract can be standardized as required and used as or in medicaments according to the invention, for example by producing tablets containing 5 – 50 mg extract and the usual solid diluents, additives, and adjuvants for production of tablets having a final weight of about 100 – 200 mg.

Example 2

Selection of solution mediators

Various substances were tested for their effectiveness as solution mediator or protective colloid during concentration. To this end, the criterion of “rimming” was used, i.e. the formation of a distinct “rim” (solidifying deposit at the periphery of the test liquid in a generally round container).

Such rimming normally occurs when concentrating a solution that contains an amorphous or resinous solid and indicates commencement of solidification upon concentration by evaporation of the solvent.

Research leading to the invention has shown that concentration of a solution of plant extract, notably of *Cimicifuga racemosa*, in the extraction liquid by evaporation leads to formation of a “rim” or “border” upon progressing increase of concentration of the solution, and that such rim tends to contain a substantial portion of the active ingredients of the extract. The result of rimming is that rim solids tend to be discarded because a homogeneous product is to be achieved. As a consequence, final extracts ob-

tained by conventional evaporation do not any longer have the same proportional composition as the primary extracts prior to concentration.

On the other hand, it has been found according to the invention that rimming can be prevented or minimized to insignificance if the solution contains what is called a solution mediator herein, and at a concentration which is sufficient to avoid "rimming".

Thus, the effectiveness of a given substance as a solution mediator for use according to the invention can be determined by a few and simple experiments by observing the amount of rimming and its dependence upon the relative amount of the substance tested for use as a solution mediator for a given concentration process.

In such experiments, poly(vinylpyrrolidone), also known as PVP or Povidone, is found to substantially preclude rimming when concentrating extracts of *Cimicifuga racemosa* and, therefore, is the most preferred solution mediator for processing extracts of *Cimicifuga racemosa* by evaporation of the extraction solvent. A PVP preferred for many purposes of the invention is obtainable commercially under the trademark Plasdone® K-29/32. This PVP has a molecular mass of about 58'000 Dalton units and a typical viscosity 2,5 mPa·s when measured at standard conditions. This type of PVP highly soluble in water as well as in a lower alkanol, methylene chloride, chloroform and other conventional organic solvents.

Another advantage of PVP is that it is an advantageous additive for processing of solid extracts, such as of *Cimicifuga racemosa*, because – since it can be allowed to remain in the final extract products because of its physiological inactivity – it will facilitate shaping methods of the type used in the production of pharmaceutical tablets. Test with PVP indicate that it can be effectively used in an amount of about 5 to about 50 % by weight, based upon the weight of the final extract or product. A range of from about 15 to about 35 % on the same basis has been found to be particularly effective.

Other substances tested but found to be suitable but less effective for extracts of *Cimicifuga racemosa* were hydroxyethyl cellulose (optionally in mixture with lecithin), maltodextrin, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, fructose, tartaric acid (optionally in the form of a salt, e.g. sodium salt).

Example 3

Analysis of Extract

The dry extract obtained according to example 1 is a fine lightly brown powder having a characteristic smell. It contains various triterpene glycosides as well as organic acids.

Analytical results of three batches prepared according to example 1 gave the following triterpene glycoside values: 8.34%, 8.84% und 10.04% or an average of 9.07% corresponding to at least 6% if calculated as 27-deoxy acetein, the substance conventionally used for standardization of extracts of *Cimicifuga racemosa*.

These values indicate a most desirable high concentration, notably when considering the fact that the final product contains about 25% of PVP. Conventional extracts of *Cimicifuga racemosa* have a substantially lower content of triterpene glycosides and appear to be less effective at equivalent dosages. The higher and apparently distinctive content of triterpene glycosides in an extract according to the invention is not due to an enrichment procedure but merely upon application of the method according to the invention providing for a recovery of active plant ingredients without loss.

In vitro testing of *Cimicifuga racemosa* extract obtained according to the invention indicates binding to distinguishable somatic receptors as well as to receptors in the central nervous system so as to make such extracts a valuable candidate for alleviating climacteric and menopausal symptoms.

Example 4

Comparative Analyses

The operation of example 1 was repeated, however once according to prior art, i.e. without use of a solution mediator during concentration (Sample A), and once with addition of PVP as described in example 1 (Sample B).

For analysis, 0.6 g of each sample were extracted with 25 ml during 15 min in an ultrasonic mixer. An aliquot each of test solution A obtained from sample A, and of test solution B obtained from sample B was transferred by means of a syringe filter into a HPLC vial, and 20 µl were injected into the HPLC apparatus. The column used was a reversed phase RP C-18, 3.0 x 120 mm, 3 µm. The mobile phase was a gradient methanol-water with acetonitrile at a flow rate of 1 ml/min. Detection was effected by a ELSD device for detection by evaporation light scattering at an evaporation temperature of

50°C and an evaporation pressure of 3.5 bar. The samples were quantified externally against a 27-deoxyactein standard to determine the triterpene glycosides (TTG).

The results are given in Figure 1 for Sample A (prior art extraction method) and in Fig. 2 for sample B (according to the invention; concentration of extract in the presence of solution mediator). As is apparent from a comparison of Fig. 1 and 2, the inventive method provides an extract having a clearly different proportional composition believed to be causal for the advantageous results of clinical testing.

10 Example 5

Clinical Testing

The objective of clinical testing was to evaluate the efficacy and safety of *Cimicifuga racemosa* in the form of tablets prepared from the extract obtained according to example 1 in the treatment of patients with menopausal syndrome.

15 The test was designed as a prospective, randomised, double-blind, placebo-controlled, parallel group comparison.

Test setting was multicentre in four outpatient general medicine clinics.

180 patients as subjects were randomised and evaluated for the intention-to-treat analysis (60 patients in three groups: placebo, *Cimicifuga racemosa* extract 6.5mg, *Cimicifuga racemosa* extract 13mg). Established diagnostic criteria for menopausal syndrome and validated assessment scales were used.

Interventions: *Cimicifuga racemosa* extract tablets, 13mg; OR 6.5mg ; OR matching placebo tablets once-daily for 12 consecutive weeks.

Main outcome measures: All variables were prospectively sought in a Protocol.

25 Statistical analysis was on an intention-to-treat basis. The main efficacy variable was change from baseline to endpoint (end of Week 12) in menopausal symptoms using the Kuppermann Index (K Index) (cf. Kuppermann H.S., "Comparative clinical evaluation of estrogen preparations by the menopausal and amenorrhoeal indices." *J Clin Endocr* 1953; 13: 88). The secondary efficacy variables were: (a) patients' self-assessment of Quality of Life; and (b) Responder Rates. Safety was evaluated by adverse event and clinical laboratory monitoring.

Results: Changes in menopausal symptoms from baseline to end of treatment (main endpoint) were significantly superior for patients receiving *Cimicifuga racemosa* extract

relative to those on placebo ($p < 0.0001$ for 13mg; $p < 0.001$ for 6.5mg). Patients' self-assessment of Quality of Life and responder rates results were similar to those for the main endpoint. Evaluation of menopausal symptoms and Quality of Life showed a high correlation ($r = -0.84$) between the two assessment instruments. The reported adverse
5 events did not raise a safety concern and hormonal levels were not affected by *Cimicifuga racemosa*.

The conclusions from this clinical test can be summarized as follows: As the indication for hormone replacement gradually shifts from prevention of chronic disease to shorter-term symptom relief, *Cimicifuga racemosa* is an effective non-hormonal alternative to hormone treatment in women with menopausal symptoms.
10

The test results are summarized in Fig. 3 representing the correlation of Quality of Life (on the ordinate in terms of visual analogue scale) versus the Kuppermann-Index (on the abszissa).

While examples were given above, it is to be understood that these examples are
15 for illustration and not limitation, and various changes will be apparent to those experienced in the art of preparing extracts from medical plants.

CLAIMS

1. A method for producing a vegetal plant extract by the steps of:
 - (A) treating a solid plant material with an extraction agent to obtain an extraction liquid containing said extract dissolved in said extraction agent;
 - (B) separating said extraction liquid from said solid plant material; and
 - (C) concentrating said extraction liquid by at least partially removing said extraction agent to produce a concentrated extract;wherein said step (C) of concentrating said extraction liquid is effected in the presence of an effective amount of a pharmacologically acceptable and physiologically inert solution mediator so as to substantially avoid loss of constituents of said extract liquid upon concentration thereof by an at least partial removal of said extraction agent.
2. The method of claim 1 wherein said extraction agent is a polar substance and preferably a C₁₋₄ alcohol or a mixture of such alcohol with water.
3. The method of claim 1 or 2 wherein said solution mediator is an organic polymer capable of being colloiddally dispersible or soluble in said extraction agent.
4. The method of claim 3 wherein said organic polymer used as said solution mediator has an average molecular mass of at least about 1000 Dalton units.
5. The method of any of claims 1 – 4 wherein said solution mediator is poly(vinylpyrrolidone).
6. The method of any of claims 1 – 4 wherein said vegetal plant is *Cimicifuga racemosa*.

7. An extract obtained by concentration of an extract fluid obtained by extracting of *Cimicifuga racemosa* with an extraction agent and concentration of said fluid extract in the presence of an effective amount of a solution mediator as defined in any of
5 claims 1 – 6.

8. Use of an extract as defined in claim 7 for production of a medicament capable of binding somatic as well as central nervous receptors so as to be suitable for
10 treating climacteric and post menopausal distress.

9. Use of an extract as defined in claim 7 for production of a medicament suitable as a substitute or complement of a hormone replacement therapy.
15

10 A medicament capable of substituting or complementing hormone replacement therapy, said medicament consisting at least in part of an extract obtained by concentration of an extract fluid from *Cimicifuga racemosa* in the presence of an effective
20 amount of a solvent mediator.

1/1




Fig. 1




Fig. 2




Fig. 3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP2004/000405

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K35/78 A61P15/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, MEDLINE, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 03/000074 A (SAKAI YASUSHI ; YOKOO YOSHIHARU (JP); KYOWA HAKKO KOGYO KK (JP)) 3 January 2003 (2003-01-03) see following English language equivalent	1-4,6
P,X	-& EP 1 407 679 A (KYOWA HAKKO KOGYO KK) 14 April 2004 (2004-04-14) paragraph '0050!; examples 1-7 comparative examples 1-4	1-4,6
X	WO 03/037096 A (GREENE JOHN BERTRAM ; BRIGHTWATER HORTICULTURE LTD (NZ)) 8 May 2003 (2003-05-08) page 5, line 26 - line 30; examples 1,2	1-4,6
X	WO 02/067962 A (LI HONGKE ; LIU DAYOU (CN); LIU DATONG (CN); LIU YIFENG (CN); QIU JINW) 6 September 2002 (2002-09-06) see following English language equivalent -/--	1-4,6

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

- *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

17 September 2004

Date of mailing of the International search report

01/10/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Pilling, S

INTERNATIONAL SEARCH REPORT

Inter — Application No
PC 1 / 01 2004/000405

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	-& US 2004/067263 A1 (LI HONGKE ET AL) 8 April 2004 (2004-04-08) example 1	1-4,6
X	----- WO 02/30436 A (KREUTER MATTHIAS HEINRICH ; TITTEL GEROLF (DE); CMI AG (DE); WAGNER HI) 18 April 2002 (2002-04-18) example 1	1-4,6
X	----- EP 0 324 197 A (LINNEA SA) 19 July 1989 (1989-07-19) example 1	1-4,6
X	----- US 2003/054050 A1 (HOFFMANN DAVID LUDWIG ET AL) 20 March 2003 (2003-03-20) paragraph '0083! - paragraph '0085!	1-4,6
X	----- US 4 985 247 A (LIU YAGUANG) 15 January 1991 (1991-01-15) examples 1,6	1-4,6
X	----- WO 01/05415 A (BRUENNER NILS ; KOEBENHAVNS UNI (DK); SPANG THOMSEN MOGENS (DK)) 25 January 2001 (2001-01-25) cited in the application page 11, line 10 - page 12, line 8	7-10
X	----- LISKE E: "Therapeutic Efficacy and Safety of Cimicifuga racemosa for Gynecologic Disorders" ADVANCES IN THERAPY, HEALTH COMMUNICATIONS, METUCHEN, NJ, US, vol. 15, no. 1, 1998, pages 45-53, XP001068814 ISSN: 0741-238X abstract page 46, line 27 - line 30	7-10
X	----- ZHENG Q Y ET AL: "Chapter 33: CIMIPURE (CIMICIFUGA RACEMOSA): A STANDARDIZED BLACK COHOSH EXTRACT WITH NOVEL TRITERPENE GLYCOSIDE FOR MENOPAUSAL WOMEN" PHYTOCHEMICALS AND PHYTOPHARMACEUTICALS, XX, XX, 2000, pages 360-370, XP001069523 page 370	7-10
X	----- PATENT ABSTRACTS OF JAPAN vol. 1997, no. 06, 30 June 1997 (1997-06-30) & JP 9 030977 A (NANBA TSUNEO; KADOTA SHIGETOSHI; KAKEN PHARMACEUT CO LTD), 4 February 1997 (1997-02-04) abstract	7-10
	----- -/--	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CH2004/000405

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE WPI Section Ch, Week 198411 Derwent Publications Ltd., London, GB; Class B04, AN 1984-065078 XP002296802 & JP 59 020298 A (SUNTORY LTD) 1 February 1984 (1984-02-01) abstract</p>	7-10
X	<p>----- BORRELLI F ET AL: "Cimicifuga racemosa: A systematic review of its clinical efficacy" EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, SPRINGER VERLAG, DE, vol. 58, no. 4, July 2002 (2002-07), pages 235-241, XP002237716 ISSN: 0031-6970 Introduction and Discussion</p>	7-10
X	<p>----- US 6 267 994 B1 (FREUDENSTEIN JOHANNES ET AL) 31 July 2001 (2001-07-31) cited in the application column 4, line 34 - line 41 -----</p>	7-10

INTERNATIONAL SEARCH REPORT

 Inter
 il Application No
 PCT/JP2004/000405

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03000074	A	03-01-2003	CA 2451144 A1 EP 1407679 A1 WO 03000074 A1 US 2004161524 A1	03-01-2003 14-04-2004 03-01-2003 19-08-2004
EP 1407679	A	14-04-2004	CA 2451144 A1 EP 1407679 A1 US 2004161524 A1 WO 03000074 A1	03-01-2003 14-04-2004 19-08-2004 03-01-2003
WO 03037096	A	08-05-2003	NZ 515182 A WO 03037096 A1	26-03-2004 08-05-2003
WO 02067962	A	06-09-2002	CN 1312253 A WO 02067962 A1 JP 2004518751 T US 2004067263 A1	12-09-2001 06-09-2002 24-06-2004 08-04-2004
US 2004067263	A1	08-04-2004	CN 1312253 A WO 02067962 A1 JP 2004518751 T	12-09-2001 06-09-2002 24-06-2004
WO 0230436	A	18-04-2002	AU 1399602 A AU 2059402 A CA 2424869 A1 CA 2424930 A1 WO 0228403 A1 WO 0230436 A1 EP 1326624 A1 EP 1333848 A1 JP 2004513092 T JP 2004510822 T US 2004161477 A1 US 2004033275 A1	22-04-2002 15-04-2002 11-04-2002 04-04-2003 11-04-2002 18-04-2002 16-07-2003 13-08-2003 30-04-2004 08-04-2004 19-08-2004 19-02-2004
EP 0324197	A	19-07-1989	CH 678150 A5 AR 240020 A1 AT 73343 T DE 3869111 D1 EP 0324197 A1 ES 2030498 T3 GR 3004878 T3 JP 1199989 A JP 2661998 B2 KR 133920 B1	15-08-1991 31-01-1990 15-03-1992 16-04-1992 19-07-1989 01-11-1992 28-04-1993 11-08-1989 08-10-1997 22-04-1998
US 2003054050	A1	20-03-2003	CA 2460203 A1 EP 1446135 A1 WO 03024470 A1	27-03-2003 18-08-2004 27-03-2003
US 4985247	A	15-01-1991	US 4886666 A US 4944946 A US 4944945 A	12-12-1989 31-07-1990 31-07-1990
WO 0105415	A	25-01-2001	AU 771581 B2 AU 5966900 A WO 0105415 A2 EP 1200107 A2	25-03-2004 05-02-2001 25-01-2001 02-05-2002

INTERNATIONAL SEARCH REPORT

Inter Application No
PCT/CN2004/000405

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
JP 9030977	A	04-02-1997	NONE	
JP 59020298	A	01-02-1984	NONE	
US 6267994	B1	31-07-2001	DE 19652183 C1 AT 205721 T AU 730372 B2 AU 4830097 A AU 5549098 A CA 2245890 A1 WO 9826791 A1 DE 59704654 D1 DK 847755 T3 EP 0847755 A1 ES 2163085 T3 HU 9901360 A2 IL 125776 A NO 975858 A PL 323617 A1	12-02-1998 15-10-2001 08-03-2001 18-06-1998 15-07-1998 25-06-1998 25-06-1998 25-10-2001 12-11-2001 17-06-1998 16-01-2002 30-08-1999 10-12-2003 15-06-1998 22-06-1998

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.